| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Bladder, Overactive | 39 | 2021 | 98 | 7.770 |
Why?
|
| Urinary Incontinence, Stress | 53 | 2023 | 211 | 6.720 |
Why?
|
| Urinary Incontinence | 53 | 2020 | 224 | 5.750 |
Why?
|
| Muscarinic Antagonists | 25 | 2012 | 59 | 4.620 |
Why?
|
| Mandelic Acids | 20 | 2013 | 20 | 3.290 |
Why?
|
| Vagina | 18 | 2022 | 185 | 3.090 |
Why?
|
| Uterine Prolapse | 15 | 2022 | 82 | 2.760 |
Why?
|
| Cystitis, Interstitial | 12 | 2023 | 55 | 2.430 |
Why?
|
| Pelvic Floor | 19 | 2022 | 88 | 2.340 |
Why?
|
| Urethra | 21 | 2023 | 108 | 2.210 |
Why?
|
| Urinary Incontinence, Urge | 11 | 2021 | 54 | 2.120 |
Why?
|
| Urinary Bladder Diseases | 13 | 2012 | 40 | 2.070 |
Why?
|
| Quality of Life | 30 | 2021 | 1869 | 1.970 |
Why?
|
| Surgical Mesh | 10 | 2022 | 126 | 1.960 |
Why?
|
| Urodynamics | 36 | 2023 | 127 | 1.930 |
Why?
|
| Pelvic Organ Prolapse | 9 | 2022 | 195 | 1.900 |
Why?
|
| Wound Healing | 7 | 2012 | 378 | 1.750 |
Why?
|
| Benzhydryl Compounds | 11 | 2012 | 46 | 1.710 |
Why?
|
| Electric Stimulation Therapy | 13 | 2021 | 59 | 1.690 |
Why?
|
| Nortropanes | 9 | 2011 | 10 | 1.620 |
Why?
|
| Female | 193 | 2023 | 50528 | 1.600 |
Why?
|
| Surveys and Questionnaires | 25 | 2020 | 2951 | 1.540 |
Why?
|
| Urologic Surgical Procedures | 11 | 2018 | 151 | 1.510 |
Why?
|
| Nocturia | 5 | 2023 | 23 | 1.460 |
Why?
|
| Gynecologic Surgical Procedures | 9 | 2019 | 183 | 1.390 |
Why?
|
| Urinary Bladder | 22 | 2023 | 259 | 1.280 |
Why?
|
| Treatment Outcome | 64 | 2023 | 9526 | 1.230 |
Why?
|
| Aged | 100 | 2020 | 21309 | 1.220 |
Why?
|
| Middle Aged | 118 | 2021 | 28794 | 1.190 |
Why?
|
| Humans | 204 | 2023 | 96382 | 1.160 |
Why?
|
| Delivery, Obstetric | 10 | 2018 | 120 | 1.140 |
Why?
|
| Fecal Incontinence | 8 | 2014 | 61 | 1.050 |
Why?
|
| Patient Satisfaction | 8 | 2018 | 509 | 1.020 |
Why?
|
| Skin | 4 | 2012 | 583 | 0.960 |
Why?
|
| Urology | 11 | 2016 | 142 | 0.950 |
Why?
|
| Terminology as Topic | 10 | 2011 | 224 | 0.940 |
Why?
|
| Prostheses and Implants | 8 | 2011 | 124 | 0.870 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 3 | 2019 | 18 | 0.860 |
Why?
|
| Suburethral Slings | 6 | 2018 | 86 | 0.840 |
Why?
|
| Pentosan Sulfuric Polyester | 5 | 2008 | 7 | 0.830 |
Why?
|
| Dimethyl Sulfoxide | 5 | 2023 | 45 | 0.810 |
Why?
|
| Cresols | 9 | 2009 | 17 | 0.800 |
Why?
|
| Ligaments | 4 | 2017 | 33 | 0.780 |
Why?
|
| Phenylpropanolamine | 8 | 2009 | 15 | 0.770 |
Why?
|
| Botulinum Toxins, Type A | 7 | 2018 | 56 | 0.740 |
Why?
|
| Skin Transplantation | 2 | 2020 | 192 | 0.720 |
Why?
|
| Menopause | 3 | 2012 | 92 | 0.720 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2012 | 91 | 0.720 |
Why?
|
| Double-Blind Method | 24 | 2013 | 1759 | 0.690 |
Why?
|
| Implantable Neurostimulators | 1 | 2021 | 12 | 0.680 |
Why?
|
| Adult | 77 | 2019 | 28968 | 0.680 |
Why?
|
| Parasympatholytics | 3 | 2009 | 17 | 0.680 |
Why?
|
| Pelvic Floor Disorders | 4 | 2014 | 61 | 0.680 |
Why?
|
| Sexuality | 2 | 2014 | 40 | 0.670 |
Why?
|
| Urologic Diseases | 5 | 2013 | 38 | 0.660 |
Why?
|
| Aged, 80 and over | 36 | 2018 | 7277 | 0.650 |
Why?
|
| Cystoscopy | 7 | 2008 | 37 | 0.630 |
Why?
|
| Pregnancy, Multiple | 3 | 2005 | 37 | 0.620 |
Why?
|
| Collagen | 5 | 2007 | 309 | 0.600 |
Why?
|
| Urination Disorders | 7 | 2004 | 52 | 0.600 |
Why?
|
| Suture Techniques | 4 | 2017 | 139 | 0.580 |
Why?
|
| Prospective Studies | 28 | 2023 | 4742 | 0.570 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 2014 | 677 | 0.550 |
Why?
|
| Urinary Catheterization | 4 | 2004 | 40 | 0.540 |
Why?
|
| Pregnancy Complications | 3 | 2018 | 360 | 0.540 |
Why?
|
| Postoperative Complications | 14 | 2011 | 2647 | 0.540 |
Why?
|
| Triamcinolone | 3 | 2023 | 22 | 0.540 |
Why?
|
| Tibial Nerve | 5 | 2021 | 13 | 0.540 |
Why?
|
| Follow-Up Studies | 22 | 2019 | 3969 | 0.540 |
Why?
|
| Counseling | 2 | 2018 | 185 | 0.530 |
Why?
|
| Rabbits | 7 | 2012 | 579 | 0.530 |
Why?
|
| Pelvic Pain | 4 | 2008 | 88 | 0.530 |
Why?
|
| Ovariectomy | 3 | 2012 | 94 | 0.500 |
Why?
|
| Retrospective Studies | 26 | 2018 | 10719 | 0.490 |
Why?
|
| Cholinergic Antagonists | 6 | 2019 | 30 | 0.480 |
Why?
|
| Anti-Inflammatory Agents | 4 | 2017 | 355 | 0.480 |
Why?
|
| Women's Health | 4 | 2010 | 113 | 0.470 |
Why?
|
| Cesarean Section | 5 | 2018 | 162 | 0.460 |
Why?
|
| Colpotomy | 2 | 2012 | 4 | 0.450 |
Why?
|
| Benzilates | 9 | 2011 | 9 | 0.450 |
Why?
|
| International Cooperation | 6 | 2010 | 132 | 0.440 |
Why?
|
| Urethral Diseases | 3 | 2006 | 15 | 0.440 |
Why?
|
| Neuromuscular Agents | 4 | 2016 | 27 | 0.440 |
Why?
|
| Recurrence | 12 | 2020 | 1235 | 0.440 |
Why?
|
| Magnetics | 4 | 2003 | 39 | 0.430 |
Why?
|
| Administration, Cutaneous | 9 | 2013 | 66 | 0.430 |
Why?
|
| Communication | 1 | 2018 | 450 | 0.430 |
Why?
|
| Male | 50 | 2021 | 46116 | 0.420 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 2014 | 17 | 0.410 |
Why?
|
| Tetrahydroisoquinolines | 3 | 2009 | 5 | 0.410 |
Why?
|
| Pain | 4 | 2023 | 415 | 0.410 |
Why?
|
| Quinuclidines | 3 | 2009 | 11 | 0.410 |
Why?
|
| Pregnancy | 17 | 2023 | 3193 | 0.410 |
Why?
|
| Durapatite | 2 | 2011 | 36 | 0.410 |
Why?
|
| Delayed-Action Preparations | 11 | 2011 | 124 | 0.400 |
Why?
|
| Rectocele | 2 | 2005 | 7 | 0.390 |
Why?
|
| Models, Economic | 1 | 2013 | 62 | 0.390 |
Why?
|
| Female Urogenital Diseases | 2 | 2010 | 8 | 0.390 |
Why?
|
| Antidiuretic Agents | 1 | 2013 | 3 | 0.390 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2013 | 12 | 0.380 |
Why?
|
| Time Factors | 15 | 2021 | 5524 | 0.380 |
Why?
|
| Symptom Assessment | 1 | 2013 | 76 | 0.380 |
Why?
|
| Safety | 2 | 2012 | 138 | 0.380 |
Why?
|
| Uterus | 1 | 2014 | 232 | 0.380 |
Why?
|
| Family Health | 1 | 2013 | 156 | 0.370 |
Why?
|
| Severity of Illness Index | 11 | 2013 | 1973 | 0.370 |
Why?
|
| Sutures | 2 | 2011 | 59 | 0.360 |
Why?
|
| Cohort Studies | 12 | 2018 | 3157 | 0.360 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2013 | 88 | 0.360 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2012 | 29 | 0.360 |
Why?
|
| Societies, Medical | 4 | 2010 | 647 | 0.360 |
Why?
|
| Drug Administration Schedule | 12 | 2013 | 836 | 0.360 |
Why?
|
| Granuloma, Foreign-Body | 1 | 2011 | 7 | 0.350 |
Why?
|
| Cross-Sectional Studies | 7 | 2023 | 1981 | 0.340 |
Why?
|
| Syringes | 2 | 2002 | 15 | 0.340 |
Why?
|
| Gynecology | 4 | 2016 | 134 | 0.340 |
Why?
|
| Multivariate Analysis | 8 | 2013 | 1007 | 0.330 |
Why?
|
| Rectal Fistula | 1 | 2011 | 21 | 0.330 |
Why?
|
| Pressure | 8 | 2006 | 167 | 0.330 |
Why?
|
| Disease Management | 1 | 2013 | 370 | 0.330 |
Why?
|
| Multiple Sclerosis | 1 | 2013 | 265 | 0.330 |
Why?
|
| Pelvis | 3 | 2005 | 104 | 0.320 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2013 | 1937 | 0.310 |
Why?
|
| Reoperation | 6 | 2020 | 715 | 0.310 |
Why?
|
| Biocompatible Materials | 1 | 2011 | 202 | 0.310 |
Why?
|
| Tartrates | 3 | 2004 | 5 | 0.310 |
Why?
|
| Abdomen | 4 | 2007 | 119 | 0.310 |
Why?
|
| Prevalence | 5 | 2019 | 1362 | 0.300 |
Why?
|
| Dermis | 2 | 2009 | 30 | 0.300 |
Why?
|
| Adolescent | 22 | 2021 | 9948 | 0.300 |
Why?
|
| Administration, Intravesical | 5 | 2023 | 40 | 0.290 |
Why?
|
| Craniosynostoses | 2 | 2021 | 76 | 0.290 |
Why?
|
| Urinary Retention | 3 | 2016 | 44 | 0.290 |
Why?
|
| Tolterodine Tartrate | 8 | 2009 | 15 | 0.290 |
Why?
|
| Work | 1 | 2009 | 15 | 0.290 |
Why?
|
| Self Report | 2 | 2021 | 352 | 0.290 |
Why?
|
| Efficiency | 1 | 2009 | 39 | 0.280 |
Why?
|
| Estrogens | 3 | 2023 | 201 | 0.280 |
Why?
|
| Recovery of Function | 1 | 2010 | 364 | 0.280 |
Why?
|
| Developmental Disabilities | 2 | 2021 | 208 | 0.270 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2008 | 51 | 0.270 |
Why?
|
| Narcotics | 1 | 2008 | 74 | 0.270 |
Why?
|
| Probability | 8 | 2008 | 354 | 0.270 |
Why?
|
| Twins, Monozygotic | 4 | 2010 | 58 | 0.260 |
Why?
|
| Granulation Tissue | 1 | 2007 | 15 | 0.250 |
Why?
|
| Risk Assessment | 10 | 2019 | 2528 | 0.250 |
Why?
|
| Surgical Tape | 1 | 2006 | 3 | 0.250 |
Why?
|
| Urological Agents | 2 | 2018 | 5 | 0.250 |
Why?
|
| Injections | 2 | 2005 | 128 | 0.240 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2008 | 156 | 0.240 |
Why?
|
| Wounds, Penetrating | 1 | 2007 | 65 | 0.240 |
Why?
|
| Hematuria | 3 | 2008 | 51 | 0.240 |
Why?
|
| Constipation | 5 | 2010 | 67 | 0.240 |
Why?
|
| Drug Monitoring | 2 | 2018 | 165 | 0.230 |
Why?
|
| Reproducibility of Results | 7 | 2013 | 2764 | 0.230 |
Why?
|
| Age Factors | 8 | 2012 | 1957 | 0.230 |
Why?
|
| Risk Factors | 12 | 2013 | 6120 | 0.230 |
Why?
|
| Logistic Models | 6 | 2008 | 1270 | 0.230 |
Why?
|
| Fascia Lata | 1 | 2005 | 7 | 0.230 |
Why?
|
| Postoperative Care | 2 | 2004 | 235 | 0.220 |
Why?
|
| Intrauterine Devices | 1 | 2005 | 33 | 0.220 |
Why?
|
| Gels | 5 | 2013 | 52 | 0.220 |
Why?
|
| Dehydration | 1 | 2005 | 22 | 0.220 |
Why?
|
| Colposcopy | 1 | 2005 | 16 | 0.220 |
Why?
|
| Dyspareunia | 1 | 2005 | 23 | 0.220 |
Why?
|
| Solvents | 1 | 2005 | 91 | 0.220 |
Why?
|
| Sweden | 3 | 2014 | 46 | 0.210 |
Why?
|
| Cystitis | 1 | 2004 | 12 | 0.210 |
Why?
|
| Psychometrics | 5 | 2014 | 355 | 0.210 |
Why?
|
| Equipment Design | 2 | 2021 | 423 | 0.210 |
Why?
|
| Surgical Procedures, Operative | 1 | 2007 | 222 | 0.210 |
Why?
|
| Anal Canal | 3 | 2011 | 94 | 0.200 |
Why?
|
| Sexual Dysfunction, Physiological | 3 | 2013 | 76 | 0.200 |
Why?
|
| Transplantation, Heterologous | 1 | 2005 | 373 | 0.200 |
Why?
|
| Urinary Tract Infections | 3 | 2021 | 87 | 0.200 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2008 | 395 | 0.200 |
Why?
|
| Eosinophilia | 1 | 2004 | 87 | 0.200 |
Why?
|
| Exercise Therapy | 2 | 2002 | 96 | 0.200 |
Why?
|
| Elective Surgical Procedures | 1 | 2005 | 169 | 0.200 |
Why?
|
| Delivery of Health Care | 1 | 2008 | 474 | 0.200 |
Why?
|
| Urination | 5 | 2012 | 39 | 0.190 |
Why?
|
| Administration, Oral | 6 | 2013 | 665 | 0.190 |
Why?
|
| Puerperal Disorders | 1 | 2003 | 36 | 0.190 |
Why?
|
| Muscle Contraction | 4 | 2014 | 266 | 0.190 |
Why?
|
| Parity | 5 | 2011 | 96 | 0.190 |
Why?
|
| Bupivacaine | 3 | 2023 | 48 | 0.180 |
Why?
|
| Random Allocation | 3 | 2012 | 312 | 0.180 |
Why?
|
| Reference Values | 7 | 2013 | 610 | 0.180 |
Why?
|
| Allografts | 2 | 2020 | 215 | 0.180 |
Why?
|
| Feasibility Studies | 3 | 2021 | 792 | 0.180 |
Why?
|
| Mothers | 1 | 2003 | 145 | 0.180 |
Why?
|
| Predictive Value of Tests | 10 | 2012 | 1759 | 0.170 |
Why?
|
| Prosthesis Implantation | 2 | 2021 | 134 | 0.170 |
Why?
|
| Polyglactin 910 | 1 | 2001 | 5 | 0.170 |
Why?
|
| Drug Therapy, Combination | 4 | 2017 | 759 | 0.170 |
Why?
|
| Trimethoprim | 1 | 2021 | 15 | 0.170 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2008 | 1089 | 0.170 |
Why?
|
| Adaptation, Psychological | 2 | 2021 | 189 | 0.170 |
Why?
|
| Urogenital Surgical Procedures | 2 | 2011 | 10 | 0.170 |
Why?
|
| Glutaral | 1 | 2000 | 5 | 0.160 |
Why?
|
| Heparin | 2 | 2023 | 181 | 0.160 |
Why?
|
| Animals | 9 | 2012 | 28471 | 0.160 |
Why?
|
| Diffusion of Innovation | 1 | 2001 | 80 | 0.160 |
Why?
|
| Transplants | 2 | 2011 | 43 | 0.160 |
Why?
|
| Epidemiologic Methods | 2 | 2010 | 60 | 0.160 |
Why?
|
| Acetylcholine Release Inhibitors | 2 | 2016 | 3 | 0.160 |
Why?
|
| Evidence-Based Medicine | 6 | 2011 | 464 | 0.150 |
Why?
|
| Electric Stimulation | 1 | 2000 | 344 | 0.150 |
Why?
|
| Incidence | 6 | 2019 | 1741 | 0.150 |
Why?
|
| Minimally Invasive Surgical Procedures | 3 | 2014 | 303 | 0.140 |
Why?
|
| Solifenacin Succinate | 3 | 2009 | 6 | 0.140 |
Why?
|
| Urinary Sphincter, Artificial | 1 | 1999 | 14 | 0.140 |
Why?
|
| Condylomata Acuminata | 3 | 1987 | 11 | 0.140 |
Why?
|
| Urinary Tract | 2 | 2013 | 34 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2011 | 975 | 0.140 |
Why?
|
| Syndrome | 3 | 2019 | 437 | 0.140 |
Why?
|
| Chronic Disease | 5 | 2010 | 970 | 0.140 |
Why?
|
| Electrodes, Implanted | 1 | 2019 | 198 | 0.140 |
Why?
|
| Pubic Bone | 3 | 2004 | 9 | 0.130 |
Why?
|
| Parturition | 1 | 2018 | 21 | 0.130 |
Why?
|
| Secondary Prevention | 3 | 2005 | 184 | 0.130 |
Why?
|
| Sleep Wake Disorders | 1 | 2019 | 133 | 0.130 |
Why?
|
| Observational Studies as Topic | 1 | 2018 | 60 | 0.130 |
Why?
|
| Sacrococcygeal Region | 1 | 2017 | 13 | 0.130 |
Why?
|
| Cryosurgery | 2 | 1989 | 76 | 0.130 |
Why?
|
| Frailty | 1 | 2019 | 102 | 0.130 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2016 | 581 | 0.130 |
Why?
|
| Orthopedic Procedures | 1 | 2019 | 155 | 0.130 |
Why?
|
| Cystostomy | 1 | 1997 | 15 | 0.130 |
Why?
|
| Pain Measurement | 2 | 2017 | 397 | 0.130 |
Why?
|
| Hernia, Ventral | 1 | 1997 | 28 | 0.130 |
Why?
|
| Odds Ratio | 5 | 2008 | 723 | 0.120 |
Why?
|
| Vulvar Diseases | 2 | 2008 | 9 | 0.120 |
Why?
|
| Hysterectomy | 2 | 2008 | 173 | 0.120 |
Why?
|
| Case-Control Studies | 3 | 2018 | 1975 | 0.120 |
Why?
|
| Clinical Trials as Topic | 2 | 2013 | 1118 | 0.120 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1998 | 252 | 0.120 |
Why?
|
| Ultrasonography | 3 | 2018 | 709 | 0.120 |
Why?
|
| Illinois | 1 | 2017 | 517 | 0.110 |
Why?
|
| Lumbosacral Plexus | 2 | 2005 | 10 | 0.110 |
Why?
|
| Combined Modality Therapy | 2 | 2010 | 1738 | 0.110 |
Why?
|
| Postoperative Period | 3 | 2006 | 322 | 0.110 |
Why?
|
| Cystocele | 2 | 2019 | 7 | 0.110 |
Why?
|
| Child | 5 | 2021 | 7540 | 0.110 |
Why?
|
| Xerostomia | 3 | 2004 | 11 | 0.110 |
Why?
|
| Prolapse | 2 | 2005 | 8 | 0.110 |
Why?
|
| Diagnosis, Differential | 2 | 2010 | 1549 | 0.110 |
Why?
|
| Physician-Patient Relations | 2 | 2018 | 574 | 0.110 |
Why?
|
| Anatomic Landmarks | 1 | 2014 | 30 | 0.110 |
Why?
|
| Analysis of Variance | 4 | 2004 | 889 | 0.110 |
Why?
|
| Young Adult | 8 | 2018 | 7318 | 0.110 |
Why?
|
| Compliance | 1 | 2014 | 16 | 0.110 |
Why?
|
| Urinary Bladder, Neurogenic | 2 | 2001 | 29 | 0.100 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1235 | 0.100 |
Why?
|
| Muscles | 2 | 1991 | 179 | 0.100 |
Why?
|
| Diagnostic Techniques, Urological | 1 | 2013 | 14 | 0.100 |
Why?
|
| Diabetes Complications | 1 | 2014 | 175 | 0.100 |
Why?
|
| Medication Therapy Management | 1 | 2013 | 18 | 0.100 |
Why?
|
| Patient Safety | 2 | 2013 | 229 | 0.100 |
Why?
|
| Surgeons | 1 | 2018 | 313 | 0.100 |
Why?
|
| Internal Medicine | 1 | 2016 | 331 | 0.090 |
Why?
|
| Drug Administration Routes | 1 | 2012 | 20 | 0.090 |
Why?
|
| Patient Compliance | 2 | 2012 | 244 | 0.090 |
Why?
|
| Evaluation Studies as Topic | 3 | 2007 | 244 | 0.090 |
Why?
|
| Confidence Intervals | 3 | 2004 | 219 | 0.090 |
Why?
|
| Sex Factors | 2 | 2012 | 1135 | 0.090 |
Why?
|
| Osteomyelitis | 2 | 2004 | 57 | 0.090 |
Why?
|
| Health Status Indicators | 1 | 2012 | 99 | 0.090 |
Why?
|
| Biofeedback, Psychology | 2 | 2007 | 13 | 0.090 |
Why?
|
| Medical History Taking | 2 | 2008 | 81 | 0.090 |
Why?
|
| Age Distribution | 1 | 2012 | 208 | 0.090 |
Why?
|
| Equipment Reuse | 2 | 2002 | 9 | 0.090 |
Why?
|
| Injections, Intramuscular | 3 | 2016 | 63 | 0.090 |
Why?
|
| Internship and Residency | 1 | 2001 | 1104 | 0.090 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 301 | 0.080 |
Why?
|
| United States | 9 | 2012 | 7976 | 0.080 |
Why?
|
| Prosthesis Failure | 1 | 2011 | 117 | 0.080 |
Why?
|
| Risk | 4 | 2006 | 659 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 3562 | 0.080 |
Why?
|
| Electromagnetic Phenomena | 2 | 2001 | 17 | 0.080 |
Why?
|
| Perineum | 1 | 2011 | 37 | 0.080 |
Why?
|
| Diverticulum | 1 | 2011 | 45 | 0.080 |
Why?
|
| Polytetrafluoroethylene | 1 | 2011 | 72 | 0.080 |
Why?
|
| Cost Savings | 2 | 2002 | 67 | 0.080 |
Why?
|
| Cognition | 3 | 2021 | 654 | 0.080 |
Why?
|
| Placebos | 1 | 2011 | 207 | 0.080 |
Why?
|
| Abscess | 1 | 2011 | 94 | 0.080 |
Why?
|
| Drug Interactions | 1 | 2011 | 238 | 0.080 |
Why?
|
| Rectum | 2 | 2010 | 150 | 0.080 |
Why?
|
| Vancomycin | 1 | 2011 | 79 | 0.080 |
Why?
|
| Intelligence Tests | 2 | 2021 | 37 | 0.080 |
Why?
|
| Physical Examination | 2 | 2010 | 148 | 0.080 |
Why?
|
| Blood Glucose | 1 | 2014 | 901 | 0.080 |
Why?
|
| Depression | 1 | 2014 | 592 | 0.080 |
Why?
|
| Radiography | 2 | 2005 | 756 | 0.080 |
Why?
|
| Abdominal Pain | 2 | 2004 | 146 | 0.080 |
Why?
|
| Muscle, Smooth | 2 | 2002 | 299 | 0.080 |
Why?
|
| Up-Regulation | 1 | 2012 | 737 | 0.080 |
Why?
|
| Sickness Impact Profile | 1 | 2009 | 29 | 0.080 |
Why?
|
| Cost of Illness | 2 | 2012 | 162 | 0.080 |
Why?
|
| Device Removal | 1 | 2011 | 170 | 0.070 |
Why?
|
| Biomarkers | 2 | 2014 | 1977 | 0.070 |
Why?
|
| Methotrexate | 2 | 1986 | 226 | 0.070 |
Why?
|
| Equipment Failure | 2 | 2006 | 119 | 0.070 |
Why?
|
| Tensile Strength | 2 | 2006 | 86 | 0.070 |
Why?
|
| Hydroxyzine | 1 | 2008 | 7 | 0.070 |
Why?
|
| Amitriptyline | 1 | 2008 | 11 | 0.070 |
Why?
|
| Child, Preschool | 2 | 2014 | 3905 | 0.070 |
Why?
|
| Histamine H1 Antagonists | 1 | 2008 | 39 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 1 | 2009 | 194 | 0.070 |
Why?
|
| Therapeutic Irrigation | 1 | 2008 | 76 | 0.070 |
Why?
|
| Muscle Hypotonia | 1 | 1988 | 47 | 0.070 |
Why?
|
| Medical Audit | 1 | 2008 | 43 | 0.070 |
Why?
|
| Diseases in Twins | 1 | 2008 | 64 | 0.070 |
Why?
|
| Office Visits | 1 | 2008 | 48 | 0.070 |
Why?
|
| Health Surveys | 4 | 2012 | 251 | 0.070 |
Why?
|
| Periodicals as Topic | 1 | 2009 | 168 | 0.070 |
Why?
|
| Child Behavior | 2 | 2021 | 51 | 0.070 |
Why?
|
| Analgesics | 1 | 2008 | 129 | 0.060 |
Why?
|
| Urethral Neoplasms | 1 | 1987 | 10 | 0.060 |
Why?
|
| Libido | 1 | 2006 | 10 | 0.060 |
Why?
|
| Marriage | 1 | 2006 | 23 | 0.060 |
Why?
|
| Preoperative Care | 2 | 2005 | 415 | 0.060 |
Why?
|
| Trophoblasts | 1 | 1986 | 35 | 0.060 |
Why?
|
| Length of Stay | 2 | 2000 | 860 | 0.060 |
Why?
|
| Elasticity | 1 | 2006 | 98 | 0.060 |
Why?
|
| RNA, Messenger | 1 | 2012 | 2041 | 0.060 |
Why?
|
| Equipment Safety | 1 | 2005 | 29 | 0.060 |
Why?
|
| Forecasting | 1 | 2007 | 292 | 0.060 |
Why?
|
| Organizations | 3 | 2010 | 17 | 0.060 |
Why?
|
| Family Practice | 1 | 2006 | 72 | 0.060 |
Why?
|
| Muscle Strength | 1 | 2005 | 49 | 0.060 |
Why?
|
| Cyanates | 1 | 2005 | 1 | 0.060 |
Why?
|
| Uterine Neoplasms | 3 | 1986 | 287 | 0.060 |
Why?
|
| Clobetasol | 1 | 2005 | 2 | 0.060 |
Why?
|
| Vulvitis | 1 | 2005 | 2 | 0.060 |
Why?
|
| Foreign-Body Reaction | 1 | 2005 | 10 | 0.060 |
Why?
|
| Nerve Block | 1 | 2005 | 54 | 0.060 |
Why?
|
| Demography | 1 | 2005 | 192 | 0.060 |
Why?
|
| Cross-Linking Reagents | 1 | 2005 | 88 | 0.050 |
Why?
|
| Benzofurans | 1 | 2004 | 12 | 0.050 |
Why?
|
| Valsalva Maneuver | 1 | 2004 | 7 | 0.050 |
Why?
|
| Life Tables | 1 | 2004 | 46 | 0.050 |
Why?
|
| Actinomycosis | 1 | 2004 | 12 | 0.050 |
Why?
|
| Cadaver | 2 | 2004 | 198 | 0.050 |
Why?
|
| Central Nervous System | 1 | 2005 | 144 | 0.050 |
Why?
|
| Vision Disorders | 1 | 2004 | 74 | 0.050 |
Why?
|
| Trophoblastic Neoplasms | 1 | 1984 | 5 | 0.050 |
Why?
|
| Pyrrolidines | 1 | 2004 | 61 | 0.050 |
Why?
|
| Receptor, Cholecystokinin B | 1 | 2004 | 3 | 0.050 |
Why?
|
| Cholecystokinin | 1 | 2004 | 15 | 0.050 |
Why?
|
| Panic Disorder | 1 | 2004 | 21 | 0.050 |
Why?
|
| Triplets | 1 | 2003 | 8 | 0.050 |
Why?
|
| Genital Diseases, Female | 1 | 2004 | 23 | 0.050 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 1984 | 27 | 0.050 |
Why?
|
| Twins | 1 | 2003 | 64 | 0.050 |
Why?
|
| Swine | 1 | 2005 | 588 | 0.050 |
Why?
|
| Salivation | 1 | 2003 | 3 | 0.050 |
Why?
|
| Northwestern United States | 1 | 2003 | 7 | 0.050 |
Why?
|
| Electromyography | 1 | 2004 | 232 | 0.050 |
Why?
|
| Sexual Behavior | 1 | 2006 | 338 | 0.050 |
Why?
|
| Indigo Carmine | 1 | 2002 | 3 | 0.050 |
Why?
|
| Obesity | 1 | 2010 | 1044 | 0.050 |
Why?
|
| Self Care | 1 | 2004 | 187 | 0.050 |
Why?
|
| Coloring Agents | 1 | 2002 | 67 | 0.050 |
Why?
|
| Congresses as Topic | 1 | 2003 | 119 | 0.050 |
Why?
|
| Bioprosthesis | 1 | 2002 | 41 | 0.040 |
Why?
|
| Methods | 4 | 1989 | 135 | 0.040 |
Why?
|
| Transducers, Pressure | 1 | 2001 | 6 | 0.040 |
Why?
|
| Hippurates | 1 | 2021 | 3 | 0.040 |
Why?
|
| Methenamine | 1 | 2021 | 3 | 0.040 |
Why?
|
| Fiber Optic Technology | 1 | 2001 | 32 | 0.040 |
Why?
|
| Sensitivity and Specificity | 3 | 1996 | 1934 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2008 | 1090 | 0.040 |
Why?
|
| Intraoperative Complications | 1 | 2002 | 194 | 0.040 |
Why?
|
| Fasciitis, Necrotizing | 1 | 2000 | 11 | 0.040 |
Why?
|
| Adolescent Development | 1 | 2021 | 27 | 0.040 |
Why?
|
| Fasciotomy | 1 | 2000 | 19 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2004 | 828 | 0.040 |
Why?
|
| Substance-Related Disorders | 2 | 1996 | 463 | 0.040 |
Why?
|
| Adolescent Behavior | 1 | 2021 | 117 | 0.040 |
Why?
|
| Parkinson Disease | 1 | 2002 | 181 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 2 | 2012 | 263 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2007 | 2528 | 0.040 |
Why?
|
| Nickel | 1 | 2019 | 14 | 0.040 |
Why?
|
| Incontinence Pads | 1 | 1999 | 4 | 0.040 |
Why?
|
| Child Development | 1 | 2021 | 169 | 0.040 |
Why?
|
| Bone Screws | 1 | 1999 | 70 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 155 | 0.040 |
Why?
|
| Posture | 2 | 1991 | 128 | 0.040 |
Why?
|
| Bisacodyl | 1 | 1978 | 1 | 0.040 |
Why?
|
| Patient Selection | 1 | 2002 | 714 | 0.040 |
Why?
|
| Proctitis | 1 | 1978 | 12 | 0.040 |
Why?
|
| Enema | 1 | 1978 | 35 | 0.040 |
Why?
|
| Bacterial Infections | 1 | 1999 | 182 | 0.030 |
Why?
|
| Suppositories | 1 | 1998 | 4 | 0.030 |
Why?
|
| Sacrum | 1 | 2018 | 81 | 0.030 |
Why?
|
| Administration, Rectal | 1 | 1998 | 13 | 0.030 |
Why?
|
| Phosphates | 1 | 1978 | 163 | 0.030 |
Why?
|
| Behavior Therapy | 2 | 1990 | 100 | 0.030 |
Why?
|
| Choriocarcinoma | 3 | 1986 | 7 | 0.030 |
Why?
|
| Urinalysis | 1 | 1997 | 34 | 0.030 |
Why?
|
| General Practice | 1 | 2016 | 9 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1984 | 1504 | 0.030 |
Why?
|
| Supine Position | 1 | 1996 | 34 | 0.030 |
Why?
|
| Fluocortolone | 1 | 1996 | 1 | 0.030 |
Why?
|
| Retinitis | 1 | 1996 | 1 | 0.030 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1978 | 242 | 0.030 |
Why?
|
| Curriculum | 1 | 2001 | 615 | 0.030 |
Why?
|
| Urologic Neoplasms | 1 | 1997 | 80 | 0.030 |
Why?
|
| Methylprednisolone | 1 | 1996 | 65 | 0.030 |
Why?
|
| Uveitis | 1 | 1996 | 35 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2018 | 400 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 324 | 0.030 |
Why?
|
| Stress, Physiological | 1 | 1996 | 250 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2007 | 303 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 2001 | 810 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 899 | 0.030 |
Why?
|
| Schizophrenia, Paranoid | 1 | 1993 | 4 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 1978 | 829 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2001 | 1198 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 1996 | 558 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 1996 | 367 | 0.020 |
Why?
|
| Crime | 1 | 1993 | 38 | 0.020 |
Why?
|
| Body Mass Index | 2 | 2008 | 837 | 0.020 |
Why?
|
| Schizophrenic Psychology | 1 | 1993 | 141 | 0.020 |
Why?
|
| Infant | 1 | 2019 | 3259 | 0.020 |
Why?
|
| Caregivers | 1 | 2014 | 194 | 0.020 |
Why?
|
| ROC Curve | 1 | 1995 | 789 | 0.020 |
Why?
|
| Canada | 1 | 2012 | 202 | 0.020 |
Why?
|
| Health Status | 1 | 2014 | 382 | 0.020 |
Why?
|
| Kidney | 1 | 1997 | 1114 | 0.020 |
Why?
|
| Alcoholism | 1 | 1993 | 193 | 0.020 |
Why?
|
| Chorionic Gonadotropin | 3 | 1986 | 69 | 0.020 |
Why?
|
| Labor Stage, Second | 1 | 2011 | 6 | 0.020 |
Why?
|
| Electrosurgery | 1 | 2011 | 10 | 0.020 |
Why?
|
| Cephalometry | 1 | 2011 | 49 | 0.020 |
Why?
|
| Violence | 1 | 1993 | 161 | 0.020 |
Why?
|
| Prognosis | 2 | 1990 | 4041 | 0.020 |
Why?
|
| Baths | 1 | 2011 | 10 | 0.020 |
Why?
|
| Therapeutic Equivalency | 1 | 2011 | 16 | 0.020 |
Why?
|
| Sunscreening Agents | 1 | 2011 | 10 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 2011 | 154 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 1999 | 2640 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2012 | 214 | 0.020 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 1990 | 30 | 0.020 |
Why?
|
| Videotape Recording | 1 | 1990 | 50 | 0.020 |
Why?
|
| Fetus | 1 | 2011 | 237 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2011 | 339 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 1990 | 161 | 0.020 |
Why?
|
| Massage | 1 | 1989 | 3 | 0.020 |
Why?
|
| Physical Therapy Modalities | 1 | 1990 | 92 | 0.020 |
Why?
|
| Dilatation | 1 | 1989 | 46 | 0.020 |
Why?
|
| Polyuria | 1 | 2009 | 7 | 0.020 |
Why?
|
| Administration, Topical | 1 | 2009 | 80 | 0.020 |
Why?
|
| Water | 1 | 2011 | 310 | 0.020 |
Why?
|
| Mass Screening | 1 | 2014 | 736 | 0.020 |
Why?
|
| Frail Elderly | 1 | 2010 | 96 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2010 | 580 | 0.020 |
Why?
|
| Algorithms | 1 | 1997 | 1974 | 0.020 |
Why?
|
| Consensus | 1 | 2010 | 304 | 0.020 |
Why?
|
| Manometry | 1 | 1987 | 42 | 0.020 |
Why?
|
| Hydatidiform Mole, Invasive | 2 | 1984 | 2 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2007 | 162 | 0.020 |
Why?
|
| Pregnancy, Tubal | 1 | 1986 | 4 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 1990 | 406 | 0.020 |
Why?
|
| Cattle | 1 | 2007 | 397 | 0.020 |
Why?
|
| Enuresis | 1 | 1986 | 4 | 0.020 |
Why?
|
| Skin Physiological Phenomena | 1 | 2006 | 18 | 0.010 |
Why?
|
| Twin Studies as Topic | 1 | 2006 | 19 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2007 | 407 | 0.010 |
Why?
|
| Premenopause | 1 | 2006 | 65 | 0.010 |
Why?
|
| Pregnancy, Ectopic | 1 | 1986 | 37 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2010 | 460 | 0.010 |
Why?
|
| Lasers | 1 | 1986 | 104 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1986 | 435 | 0.010 |
Why?
|
| Postmenopause | 1 | 2006 | 108 | 0.010 |
Why?
|
| Vulva | 1 | 2005 | 24 | 0.010 |
Why?
|
| Focus Groups | 1 | 2006 | 208 | 0.010 |
Why?
|
| Cell Division | 1 | 1986 | 689 | 0.010 |
Why?
|
| Biomedical Research | 1 | 2010 | 456 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1986 | 945 | 0.010 |
Why?
|
| Anesthetics, Local | 1 | 2005 | 85 | 0.010 |
Why?
|
| Linear Models | 1 | 2006 | 422 | 0.010 |
Why?
|
| Drug Delivery Systems | 1 | 2006 | 196 | 0.010 |
Why?
|
| Shock, Septic | 1 | 1986 | 136 | 0.010 |
Why?
|
| Genital Neoplasms, Female | 1 | 1986 | 116 | 0.010 |
Why?
|
| Rectus Abdominis | 1 | 2004 | 41 | 0.010 |
Why?
|
| Dermatitis, Contact | 1 | 2003 | 9 | 0.010 |
Why?
|
| Surgical Instruments | 1 | 2004 | 69 | 0.010 |
Why?
|
| Staphylococcal Infections | 1 | 1986 | 285 | 0.010 |
Why?
|
| Biopsy | 1 | 1986 | 1196 | 0.010 |
Why?
|
| Headache | 1 | 2003 | 79 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2004 | 374 | 0.010 |
Why?
|
| Hydatidiform Mole | 1 | 1982 | 6 | 0.010 |
Why?
|
| Diarrhea | 1 | 2003 | 180 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2004 | 708 | 0.010 |
Why?
|
| Electromagnetic Fields | 1 | 2000 | 26 | 0.010 |
Why?
|
| Analgesics, Opioid | 1 | 2005 | 529 | 0.010 |
Why?
|
| Suction | 1 | 1999 | 45 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 2002 | 224 | 0.010 |
Why?
|
| Debridement | 1 | 1999 | 61 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 2001 | 167 | 0.010 |
Why?
|
| Genotype | 1 | 2004 | 1879 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2004 | 1434 | 0.010 |
Why?
|
| Treatment Refusal | 1 | 1996 | 69 | 0.010 |
Why?
|
| Bacteria | 1 | 1999 | 531 | 0.010 |
Why?
|
| Depressive Disorder | 1 | 1996 | 229 | 0.010 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 1996 | 502 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 1999 | 863 | 0.010 |
Why?
|
| Bipolar Disorder | 1 | 1996 | 403 | 0.010 |
Why?
|
| Pregnancy Tests | 1 | 1986 | 2 | 0.000 |
Why?
|
| Amenorrhea | 1 | 1986 | 28 | 0.000 |
Why?
|
| Hysterosalpingography | 1 | 1986 | 7 | 0.000 |
Why?
|
| Hemoperitoneum | 1 | 1986 | 4 | 0.000 |
Why?
|
| Uterine Hemorrhage | 1 | 1986 | 22 | 0.000 |
Why?
|
| Drug Evaluation | 1 | 1986 | 109 | 0.000 |
Why?
|
| Laparoscopy | 1 | 1986 | 780 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1982 | 2481 | 0.000 |
Why?
|